Cargando…
Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate...
Autores principales: | Pemmaraju, Naveen, Sweet, Kendra L., Stein, Anthony S., Wang, Eunice S., Rizzieri, David A., Vasu, Sumithira, Rosenblat, Todd L., Brooks, Christopher L., Habboubi, Nassir, Mughal, Tariq I., Kantarjian, Hagop, Konopleva, Marina, Lane, Andrew A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9462530/ https://www.ncbi.nlm.nih.gov/pubmed/35820082 http://dx.doi.org/10.1200/JCO.22.00034 |
Ejemplares similares
-
Recent developments in the treatment of blastic plasmacytoid dendritic cell neoplasm
por: Economides, Minas P., et al.
Publicado: (2019) -
Treatment of leptomeningeal disease in blastic plasmacytoid dendritic cell neoplasm following tagraxofusp-erzs induction
por: Vangala, Deepak B., et al.
Publicado: (2022) -
Foot gangrene following Tagraxofusp treatment for blastic plasmacytoid dendritic cell neoplasm: Case report
por: Sibai, Jad, et al.
Publicado: (2022) -
Tagraxofusp for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Brief Report on Emerging Data
por: Beziat, Guillaume, et al.
Publicado: (2020) -
Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD
por: Pemmaraju, Naveen, et al.
Publicado: (2022)